Shock, Septic
75
9
11
33
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
10.7%
8 terminated out of 75 trials
80.5%
-6.0% vs benchmark
19%
14 trials in Phase 3/4
9%
3 of 33 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 33 completed trials
Clinical Trials (75)
Multimodal Vasopressor Strategy in Septic Shock
Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis
Vasopressin Hemodynamic Response as a Septic Shock Subphenotype Indicator
Early Intravenous Hydrocortisone in Sepsis
Personalized Dose Optimization of Amikacin Guided by Pharmacokinetic Modeling Software in Patients With Septic Shock
Comparison of Peripheral Perfusion Indicators and Lactate Levels
Strain Echocardiography During Septic Shock : an Observational Pilot Study
Prospective Validation of Clini-biological Parameters Including Initial Hemostasis, Which Improve the Prediction of Death at 1 Month Among Patients With Septic Shock
Early Severe Illness TrAnslational BioLogy InformaticS in Humans
L-carnitine as an Adjunct Treatment for Septic Shock Patients With Acute Kidney Injury
Early Initiated Vasopressor Therapy in the Emergency Department
"Mini Fluid Challenge Assessment: a Comparison Among Three Hemodynamic Tools"
Fluid Overload Quantification in Septic Shock
Management of Shock in Children With SAM or Severe Underweight and Diarrhea
Sevoflurane Sedation in Patients With Septic Shock
Types of Photoplethysmographic Waves in Adult Patients with Septic Shock
Vitamin C, Hydrocortisone and Thiamine for Septic Shock
Hemodynamic Phenotype-Based,Capillary Refill Time-Targeted Resuscitation In Early Septic Shock:ANDROMEDA-SHOCK-2
Pituitary Function After Recovery From Septic Shock Among ICU Survivors
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM (Nangibotide) in Patients With Septic Shock